Vivo Capital, LLC Verona Pharma PLC Transaction History

Vivo Capital, LLC

  • $512 Million
  • Q4 2024

A detailed history of Vivo Capital, LLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Vivo Capital, LLC holds 2,283,975 shares of VRNA stock, worth $140 Million. This represents 20.7% of its overall portfolio holdings.

Number of Shares
2,283,975
Previous 3,549,758 35.66%
Holding current value
$140 Million
Previous $102 Million 3.86%
% of portfolio
20.7%
Previous 14.95%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$28.71 - $47.02 $36.3 Million - $59.5 Million
-1,265,783 Reduced 35.66%
2,283,975 $106 Million
Q2 2024

Aug 14, 2024
SELL
$11.48 - $17.02 $693,610 - $1.03 Million
-60,419 Reduced 1.67%
3,549,758 $51.3 Million
Q1 2024

Apr 22, 2024
SELL
$15.3 - $20.24 $9.79 Million - $12.9 Million
-639,741 Reduced 15.05%
3,610,177 $58.1 Million
Q3 2022

Nov 14, 2022
BUY
$4.14 - $13.59 $6.21 Million - $20.4 Million
1,500,000 Added 54.55%
4,249,918 $43.4 Million
Q3 2021

Nov 15, 2021
SELL
$5.29 - $6.35 $1.58 Million - $1.9 Million
-298,589 Reduced 9.79%
2,749,918 $15.1 Million
Q3 2020

Nov 13, 2020
BUY
$4.45 - $10.2 $6.92 Million - $15.9 Million
1,555,556 Added 104.19%
3,048,507 $19 Million
Q1 2020

May 15, 2020
BUY
$2.16 - $7.28 $3.22 Million - $10.9 Million
1,492,951 New
1,492,951 $6.15 Million
Q3 2019

Nov 13, 2019
SELL
$4.03 - $5.44 $6.02 Million - $8.12 Million
-1,492,951 Closed
0 $0
Q3 2017

Nov 13, 2017
BUY
$11.96 - $16.95 $17.9 Million - $25.3 Million
1,492,951
1,492,951 $22.9 Million

Others Institutions Holding VRNA

# of Institutions
218
Shares Held
70.5M
Call Options Held
1.4M
Put Options Held
299K
View Full List

About Verona Pharma plc

VRNA Quotes by TradingView
  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $3.74B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Vivo Capital, LLC Portfolio

Follow Vivo Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vivo Capital, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email